MDWD News and Press, MediWound Ltd. From 02/03/23

YAVNE, Israel, Feb. 03, 2023 (GLOBE NEWSWIRE) -- MediWound Ltd. (NASDAQ: MDWD) (the “Company”), a fully integrated biopharmaceutical company focused on next-generation biotherapeutic solutions for tissue repair and regeneration, today announced that it has entered into a definitive ...

Summary Today, we take a deeper look at MediWound, an Israeli-based biopharma with some recent marketing application approvals. Those 'wins' has triggered a 50% rally in the stock, and the company continues to develop its pipeline as well. An investment analysis follows in the parag...

Potential to become the new standard of care for eschar removal in patients with deep partial- and/or full- thickness thermal burns Triggers $7.5 million milestone payment from Vericel Corporation; NexoBrid is anticipated to be commercially available in the U.S. in the second quarter of...

MediWound ( NASDAQ: MDWD ) said on Friday its Japanese partner Kaken Pharma had gained marketing approval of burn treatment, NexoBrid, in Japan. Kaken has the exclusive right to market and distribute NexoBrid in Japan and expects to launch it in the summer of 2023. T...

Japan is the first country in the world to approve NexoBrid for people of all ages; pediatric and adult populations Exclusive marketing and distribution agreement with Kaken Pharmaceutical Co., Ltd. YAVNE, Israel, Dec. 23, 2022 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), ...

MediWound ( NASDAQ: MDWD ) on Tuesday said its treatment for severe burns NexoBrid had been granted marketing approval in Switzerland. MDWD's NexoBrid is a topically administered biological product that removes burn tissue in patients with thermal burns. "MediWound has signed an a...

NexoBrid gain ed marketing approval in Switzerland ; l aunch expected first quarter 2023 Launch in France expected in third quarter 2023 YAVNE, Israel, Dec. 20, 2022 (GLOBE NEWSWIRE) -- MediWound Ltd. (NASDAQ: MDWD), a fully inte...

MW005 s hown to b e s afe and w ell-tolerated D ata p rovides c linical e fficacy p roof-of- c oncept based on complete clearance of target lesions YAVNE, Israel, Dec. 19, 2022 (GLOBE NEWSWIRE)...

YAVNE, Israel, Dec. 13, 2022 (GLOBE NEWSWIRE) -- MediWound Ltd. (NASDAQ: MDWD), a fully integrated biopharmaceutical company focused on next-generation biotherapeutic solutions for tissue repair and regeneration, today announced it has gained marketing approval of NexoBrid ® in India. Me...

YAVNE, Israel, Dec. 05, 2022 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD) (“ MediWound ” or the “ Company ”), a fully integrated biopharmaceutical company focused on next-generation biotherapeutic solutions for tissue repair and regeneration, today announc...